Literature DB >> 27461022

Use of Antidepressants During Pregnancy?: What to Consider when Weighing Treatment with Antidepressants Against Untreated Depression.

Maria Muzik1,2,3, Susan E Hamilton4.   

Abstract

Introduction Mood disorders impact many pregnant women, particularly those who have experienced symptoms prior to conception, and there are significant barriers, including stigma and access, to seeking and receiving appropriate treatments. Antidepressants are a helpful option in treating perinatal depression, but research on risks and benefits of antidepressant use in pregnancy is difficult given lack of "gold standard" comparative trials. Methods This paper summarizes current state of knowledge on the safety of antidepressants during pregnancy by providing a summary of the literature published in the past 3 years (January 2013-October 2015). We identified 21 reviews and meta-analyses that were included in this summary report. This report is meant to provide a user-friendly, yet comprehensive guide summarizing the abundant, and in part contradicting, literature on risks and benefits of antidepressants during pregnancy, in order to assist busy primary care prescribers in educating their patients. Our goal is also to contrast the risks/benefits of untreated depression in pregnancy versus treatment with antidepressant medication in pregnancy, and in such support prescribers in their decision-making. Results The past 3 years have yielded an abundance of publications on the topic, in part, with conflicting findings adding to confusion and concern among providers, patients, and their families. Many reported studies have methodological problems limiting their impact. Data on adverse effects of medications on pregnancy and fetal outcomes have to be weighed against the impact of untreated illness and poor health habits associated with untreated illness on the same outcomes. Discussion Medical-decision making is often complex and seldom free of risks. Obviously, as providers we cannot guarantee that fetal exposure to antidepressants is totally free of risk, yet this is true for any medicine taken in pregnancy. However, to date, perinatal psychiatry has collected enough evidence to suggest that, if the clinical picture warrants it, the use of many antidepressants, especially the SSRIs, is favorable compared to exposing mother and child to untreated depressive illness.

Entities:  

Keywords:  Antidepressants; Guide for decision-making; Pregnancy; Summary of literature; Teratogenicity; Untreated depression

Mesh:

Substances:

Year:  2016        PMID: 27461022     DOI: 10.1007/s10995-016-2038-5

Source DB:  PubMed          Journal:  Matern Child Health J        ISSN: 1092-7875


  55 in total

1.  Use of antidepressant medication in the United States during pregnancy, 2002-2010.

Authors:  Matthew Ryan Meunier; Ian M Bennett; Andrew S Coco
Journal:  Psychiatr Serv       Date:  2013-11-01       Impact factor: 3.084

Review 2.  Neuroendocrine and behavioral consequences of untreated and treated depression in pregnancy and lactation.

Authors:  Eszter Csaszar; Kristina Melichercikova; Michal Dubovicky
Journal:  Neuro Endocrinol Lett       Date:  2014       Impact factor: 0.765

Review 3.  Antidepressant use in pregnancy: a critical review focused on risks and controversies.

Authors:  N Byatt; K M Deligiannidis; M P Freeman
Journal:  Acta Psychiatr Scand       Date:  2012-12-14       Impact factor: 6.392

4.  The impact of a brief obstetrics clinic-based intervention on treatment use for perinatal depression.

Authors:  Heather A Flynn; Heather A O'Mahen; Lynn Massey; Sheila Marcus
Journal:  J Womens Health (Larchmt)       Date:  2006-12       Impact factor: 2.681

Review 5.  Maternal use of antidepressant or anxiolytic medication during pregnancy and childhood neurodevelopmental outcomes: a systematic review.

Authors:  Hanan El Marroun; Tonya White; Frank C Verhulst; Henning Tiemeier
Journal:  Eur Child Adolesc Psychiatry       Date:  2014-05-27       Impact factor: 4.785

6.  Thalidomide: the tragedy of birth defects and the effective treatment of disease.

Authors:  James H Kim; Anthony R Scialli
Journal:  Toxicol Sci       Date:  2011-04-19       Impact factor: 4.849

7.  The comprehensive management of pregnant women with major mood disorders: a case study involving phenelzine, lithium, and quetiapine.

Authors:  Jacqueline Frayne; Thinh Nguyen; Rolland Kohan; Nick De Felice; Jonathan Rampono
Journal:  Arch Womens Ment Health       Date:  2013-11-08       Impact factor: 3.633

Review 8.  Maternal use of SSRIs, SNRIs and NaSSAs: practical recommendations during pregnancy and lactation.

Authors:  S D Sie; J M B Wennink; J J van Driel; A G W te Winkel; K Boer; G Casteelen; M M van Weissenbruch
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2012-11       Impact factor: 5.747

9.  Prenatal mood disturbance predicts sleep problems in infancy and toddlerhood.

Authors:  Thomas G O'Connor; Peter Caprariello; Emma Robertson Blackmore; Alice M Gregory; Vivette Glover; Peter Fleming
Journal:  Early Hum Dev       Date:  2006-09-26       Impact factor: 2.079

Review 10.  Specific SSRIs and birth defects: Bayesian analysis to interpret new data in the context of previous reports.

Authors:  Jennita Reefhuis; Owen Devine; Jan M Friedman; Carol Louik; Margaret A Honein
Journal:  BMJ       Date:  2015-07-08
View more
  9 in total

1.  Childhood adversity and sleep are associated with symptom severity in perinatal women presenting for psychiatric care.

Authors:  Rena A Menke; Leslie Swanson; Nora L Erickson; Greta Reglan; Stephanie Thompson; Katherine Harris Bullard; Katherine Rosenblum; Juan P Lopez; Maria Muzik
Journal:  Arch Womens Ment Health       Date:  2018-10-01       Impact factor: 3.633

2.  Selective serotonin reuptake inhibitors and venlafaxine in pregnancy: Changes in drug disposition.

Authors:  Andreas Austgulen Westin; Malin Brekke; Espen Molden; Eirik Skogvoll; Olav Spigset
Journal:  PLoS One       Date:  2017-07-14       Impact factor: 3.240

3.  Self-reported perinatal depressive symptoms and postnatal symptom severity after treatment with antidepressants in pregnancy: a cross-sectional study across 12 European countries using the Edinburgh Postnatal Depression Scale.

Authors:  Angela Lupattelli; Michael J Twigg; Ksenia Zagorodnikova; Myla E Moretti; Mariola Drozd; Alice Panchaud; Andre Rieutord; Romana Gjergja Juraski; Marina Odalovic; Debra Kennedy; Gorazd Rudolf; Herbert Juch; Hedvig Nordeng
Journal:  Clin Epidemiol       Date:  2018-06-06       Impact factor: 4.790

4.  Perinatal mood and anxiety disorders, serious mental illness, and delivery-related health outcomes, United States, 2006-2015.

Authors:  Kimberly McKee; Lindsay K Admon; Tyler N A Winkelman; Maria Muzik; Stephanie Hall; Vanessa K Dalton; Kara Zivin
Journal:  BMC Womens Health       Date:  2020-07-23       Impact factor: 2.809

Review 5.  Risks of using SSRI / SNRI antidepressants during pregnancy and lactation.

Authors:  Michal Dubovicky; Kristína Belovicova; Kristína Csatlosova; Eszter Bogi
Journal:  Interdiscip Toxicol       Date:  2017-09

6.  The German Guidelines for the treatment of anxiety disorders: first revision.

Authors:  Borwin Bandelow; Antonia M Werner; Ina Kopp; Sebastian Rudolf; Jörg Wiltink; Manfred E Beutel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-10-05       Impact factor: 5.760

7.  Building Bridges in Child and Adolescent Psychiatry Training: Providing Maternal-Infant Mental Health Care Through Creation of a Perinatal Collaborative Care Program.

Authors:  Misty C Richards
Journal:  Acad Psychiatry       Date:  2021-11-29

8.  Cross-cultural adaptation and psychometric properties of the Chinese version of the postpartum depression literacy scale.

Authors:  Pingping Guo; Nianqi Cui; Minna Mao; Xuehui Zhang; Dandan Chen; Ping Xu; Xiaojuan Wang; Wei Zhang; Qiong Zheng; Le Zhang; Zhenzhen Xiang; Yin Jin; Suwen Feng
Journal:  Front Psychol       Date:  2022-08-09

Review 9.  Treatment of anxiety disorders.

Authors:  Borwin Bandelow; Sophie Michaelis; Dirk Wedekind
Journal:  Dialogues Clin Neurosci       Date:  2017-06       Impact factor: 5.986

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.